Images in Immunotherapy and PrecisionOncology: Advanced Basal Cell Carcinoma

A 62-year-old man presented with a slowly growing, painless lesion on his face. This eventually led to a progressive left-eye visionlesion, and the patient was subsequently diagnosed with advanced basal cell carcinoma (BCC). Of note, BCC involving cranialnerves is extremely rare, making this case unique and important to highlight. Standard treatment options for BCC involve surgery,radiation, or platinum-based chemotherapy. However, targeted therapies such as sonidegib and vismodegib - sonic hedgehogpathway inhibitors - have emerged that have been approved for treating BCC, as have anti-PD1 immunotherapies, such ascemiplimab, with their success likely based on the high tumor mutational burden seen in some of these tumors. Epidermal growthfactor receptor (EGFR) inhibitors also serve a role in treating this condition as well. Molecular studies on metastatic/advanced BCCand other rare malignancies may inform treatment therapeutic decisions.